Julie Jorns, MD

Publications

• Immunohistochemistry in the Differential Diagnosis of Triple Negative Breast Carcinoma and High-grade Serous Carcinoma: Old and New Markers.

  (Jain PV, Molina M, Moh M, Bishop E, Rader JS, Jorns JM.) Appl Immunohistochem Mol Morphol. 2024 Nov-Dec 01;32(10):456-461 PMID: 39506288 SCOPUS ID: 2-s2.0-85208688860 11/12/2024

• Examining the false-negative rate of a negative axillary node ultrasound-guided core needle biopsy in breast cancer patients undergoing upfront surgery.

  (Rogers C, Zeien S, Puccetti K, Jorns JM, Kong AL, Cherian S, Cortina CS.) Am J Surg. 2024 Oct 24;239:116047 PMID: 39481279 SCOPUS ID: 2-s2.0-85207766054 11/01/2024

• Improving resource utilization: Axillary lymph node core biopsy triaging for lymphoma.

  (Dernell C, Astle J, Bogachkov A, Reimer S, Wadhwa A, Majidi SS, Canales B, Jorns JM.) Am J Clin Pathol. 2024 Sep 03;162(3):227-232 PMID: 38591770 SCOPUS ID: 2-s2.0-85203077751 04/09/2024

• Divergent Cellular Expression Patterns of PD-L1 and PD-L2 Proteins in Breast Cancer.

  (Jorns JM, Sun Y, Kamaraju S, Cheng YC, Kong A, Yen T, Patten CR, Cortina CS, Chitambar CR, Rui H, Chaudhary LN.) J Pers Med. 2024 Apr 29;14(5) PMID: 38793060 PMCID: PMC11121947 SCOPUS ID: 2-s2.0-85194400127 05/25/2024

• Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations

  (Cobb AN, Czaja R, Jorns J, Cortina CS.) Current Breast Cancer Reports. June 2024;16(2):150-160 SCOPUS ID: 2-s2.0-85188604136 06/01/2024

• Selective breast/gynecologic pathology fellowship training in the United States: Experience of program directors.

  (Desouki MM, Hagemann IS, Khoury T, Fadare O, Bhargava R, Clark JL, Deavers MT, Jorns JM, Khan A, Cosar EF, Karabakhtsian RG, Klein ME, Pinto A, Ali M.) Acad Pathol. 2024;11(1):100103 PMID: 38380270 PMCID: PMC10877681 02/21/2024

• Deep Learning for Automated Detection of Breast Cancer in Deep Ultraviolet Fluorescence Images with Diffusion Probabilistic Model

  (Ghahfarokhi SS, To T, Jorns J, Yen T, Yu B, Ye DH.) Proceedings - International Symposium on Biomedical Imaging. 2024 SCOPUS ID: 2-s2.0-85203394645 01/01/2024

• Axillary node evaluation and biopsy: Predictors of malignancy based on sonographic morphology and mode of detection.

  (Wadhwa A, Majidi SS, Reimer S, Bogachkov A, Dernell C, Astle J, Jorns JM.) Clin Imaging. 2023 Oct 25;104:110014 PMID: 39492227 11/04/2024

• Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.

  (Chaudhary LN, Jorns JM, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo MB, Kong AL, Patten C, Yen T, Cortina CS, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang Y, Chervoneva I, Weil E, Chitambar CR, Rui H.) Breast Cancer Res Treat. 2023 Oct;201(3):387-396 PMID: 37460683 PMCID: PMC10795510 SCOPUS ID: 2-s2.0-85164922339 07/18/2023

• Axillary node evaluation and biopsy: Predictors of malignancy based on sonographic morphology and mode of detection

  (Wadhwa A, Majidi SS, Reimer S, Bogachkov A, Dernell C, Astle J, Jorns JM.) Clinical Imaging. December 2023;104 SCOPUS ID: 2-s2.0-85174892942 12/01/2023

• Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)-like change: clinicopathological and molecular characteristics

  (Jorns JM, Farooq A, Puzyrenko A, Jarzembowski J, Thike AA, Nasir NDM, Ng CCY, Liu W, Lee JY, Lim AH, Guan P, Teh BT, Tan PH.) Histopathology. September 2023;83(3):357-365 SCOPUS ID: 2-s2.0-85156108581 09/01/2023

• Deep learning classification of deep ultraviolet fluorescence images toward intra-operative margin assessment in breast cancer.

  (To T, Lu T, Jorns JM, Patton M, Schmidt TG, Yen T, Yu B, Ye DH.) Front Oncol. 2023;13:1179025 PMID: 37397361 PMCID: PMC10313133 SCOPUS ID: 2-s2.0-85164403482 07/03/2023